Publicaciones científicas sobre los diagnósticos no invasivos de BioPredictive
Estudios revisados por pares que validan los diagnósticos por análisis de sangre de BioPredictive para enfermedades hepáticas — desde cohortes de desarrollo pioneras hasta metaanálisis a largo plazo.
18/435
Coincidencias para
“direct-acting antiviral agents”
-
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
### Background & Aims Patients with chronic hepatitis C virus infection and advanced fibrosis…
-
Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.
### Background Direct antiviral agents (DAA) showed very good results in terms of…
-
HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
…New direct-acting antiviral agent (DAA) combination therapy has not yet been…
-
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. Review
Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C…
-
Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.
### Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for…
-
Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
### Background In the UNITY-3 study, 96% sustained virologic response (SVR12) rate…
-
Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis.
…successful treatment with telaprevir-based antiviral regimens. We performed a retrospective analysis…
-
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.
-
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. Key publication
### Background & Aims The Liver Cancer Risk test algorithm (LCR1-LCR2) is a…
-
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication
…Specifically, direct-acting antiviral agents with dramatically improved rates of virological clearance…
-
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication
-
Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Meta Analysis
### Background Liver biopsy and virological end points are standard references for assessing…
-
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
-
Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection Key publication
These are the first guidelines dealing with hepatitis C treatment produced by…
-
Prise en charge des personnes infectées par les virus de l’hépatite B ou de l’hépatite C — Rapport de recommandations 2014 Key publication
-
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication
-
Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection
These are the first World Health Organization (WHO) guidelines for the prevention…
-
Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
### Background Excessive alcohol consumption may lead to the development of alcohol-related…
Mostrando la lista completa de resultados. La página se renderiza en el servidor y no está paginada.